Table 1.
Clinical Parameters of Subjects
| Patient | Cognitive Status | Gender | Age (yrs) | cART | CPE | CD4 Nadir (cells/mm3) | CD4 (cells/mm3) | CSF WBC | Viral Load (copies/mL) | |
|---|---|---|---|---|---|---|---|---|---|---|
| CSF | Plasma | |||||||||
| PR1 | NC | F | 44 | EFV, TDF+FTC | 6 | 28 | 194 | 2 | UND | UND |
| PR2 | NC | F | 40 | ABC+3TC, ATV | 7 | 69 | 134 | 3 | 11,871 | 100,000 |
| PR3 | NC | F | 25 | AZT+3TC, NFV | 7 | 379 | 379 | 1 | UND | 76,563 |
| PR4 | HAND | F | 34 | SQV, LPV/r, TDF+FTC | 8 | 111 | 197 | 6 | UND | UND |
| PR5 | HAND | F | 42 | ATV, ABC+3TC | 7 | 111 | 314 | 4 | UND | UND |
| PR6 | HAND | F | 51 | None | 300 | 337 | 10 | UND | 413 | |
| HI1 | NC | M | 53 | LPV/r, EFV | 5 | 137 | 742 | 0 | UND | UND |
| HI2 | NC | M | 61 | ABC, IDV, EFV, RTV | 9 | 151 | 331 | 2 | UND | UND |
| HI3 | NC | M | 37 | AZT+3TC, EFV | 8 | 302 | 628 | 1 | UND | UND |
| HI4 | HAND | M | 35 | TDF, EFV, ddI | 5 | 72 | 98 | 0 | 299 | 85,386 |
| HI5 | HAND | M | 38 | 3TC, d4T, NFV | 5 | 197 | 262 | 1 | UND | 137 |
| HI6 | HAND | F | 37 | TDF, d4T, LPV/r | 6 | 34 | 40 | 9 | 2,561 | 125,872 |
| Median (tertiles) | 39 (37, 43) | 7 (6, 7) | 124.0 (83.3, 177.7) | 288.0 (194.9, 334.5) | 2 (1, 4) | |||||
cART: combined antiretroviral treatment; CPE: CNS penetration effect [21, 26]; White blood cell (WBC) values are counts per mL; 2Viral Load (VL) were considered undetectable (UND) if they contained copies ≤ 50 copies/mL; EFV: Efavirenz, TDF: Tenofovir, FTC: Emtricitabine, ABC: Abacavir, 3TC: Lamivudine, ATV: Atazanavir, AZT: Zidovudine, NFV: Nelfinavir, SQV: Saquinavir, LPV/r: Lopinavir/Ritonavir, IDV: Indinavir, RTV: Ritonavir, ddI: Didanosine, d4T: Stavudine